Literature DB >> 22350026

Epigallocatechin-3-gallate potentiates curcumin's ability to suppress uterine leiomyosarcoma cell growth and induce apoptosis.

Akiko Kondo1, Takashi Takeda, Bin Li, Kenji Tsuiji, Mari Kitamura, Tze Fang Wong, Nobuo Yaegashi.   

Abstract

BACKGROUND: Uterine leiomyosarcoma (LMS) has an unfavorable response to standard chemotherapeutic regimens. Two natural occurring compounds, curcumin and epigallocatechin gallate (EGCG), are reported to have anti-cancer activity. We previously reported that curcumin reduced uterine LMS cell proliferation by targeting the AKT-mTOR pathway. However, challenges remain in overcoming curcumin's low bioavailability.
METHODS: The human LMS cell line SKN was used. The effect of EGCG, curcumin or their combination on cell growth was detected by MTS assay. Their effect on AKT, mTOR, and S6 was detected by Western blotting. The induction of apoptosis was determined by Western blotting using cleaved-PARP specific antibody, caspase-3 activity and TUNEL assay. Intracellular curcumin level was determined by a spectrophotometric method. Antibody against EGCG cell surface receptor, 67-kDa laminin receptor (67LR), was used to investigate the role of the receptor in curcumin's increased potency by EGCG.
RESULTS: In this study, we showed that the combination of EGCG and curcumin significantly reduced SKN cell proliferation more than either drug alone. The combination inhibited AKT, mTOR, and S6 phosphorylation, and induced apoptosis at a much lower curcumin concentration than previously reported. EGCG enhanced the incorporation of curcumin. 67LR antibody partially rescued cell proliferation suppression by the combination treatment, but was not involved in the EGCG-enhanced intracellular incorporation of curcumin.
CONCLUSIONS: EGCG significantly lowered the concentration of curcumin required to inhibit the AKT-mTOR pathway, reduce cell proliferation and induce apoptosis in uterine LMS cells by enhancing intracellular incorporation of curcumin, but the process was independent of 67LR.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22350026     DOI: 10.1007/s10147-012-0387-7

Source DB:  PubMed          Journal:  Int J Clin Oncol        ISSN: 1341-9625            Impact factor:   3.402


  38 in total

1.  Establishment of a human leiomyosarcoma cell line.

Authors:  I Ishiwata; S Nozawa; S Nagai; S Kurihara; A Mikata
Journal:  Cancer Res       Date:  1977-03       Impact factor: 12.701

2.  [Antibacterial and anti-hemolysin activities of tea catechins and their structural relatives].

Authors:  M Toda; S Okubo; H Ikigai; T Shimamura
Journal:  Nihon Saikingaku Zasshi       Date:  1990-03

3.  Chemoprevention of human prostate cancer by oral administration of green tea catechins in volunteers with high-grade prostate intraepithelial neoplasia: a preliminary report from a one-year proof-of-principle study.

Authors:  Saverio Bettuzzi; Maurizio Brausi; Federica Rizzi; Giovanni Castagnetti; Giancarlo Peracchia; Arnaldo Corti
Journal:  Cancer Res       Date:  2006-01-15       Impact factor: 12.701

Review 4.  Possible mechanisms of the cancer-preventive activities of green tea.

Authors:  Chung S Yang; Shengmin Sang; Joshua D Lambert; Zhe Hou; Jihyeung Ju; Gang Lu
Journal:  Mol Nutr Food Res       Date:  2006-02       Impact factor: 5.914

5.  (-)-Epigallocatechin-3-gallate blocks the induction of nitric oxide synthase by down-regulating lipopolysaccharide-induced activity of transcription factor nuclear factor-kappaB.

Authors:  Y L Lin; J K Lin
Journal:  Mol Pharmacol       Date:  1997-09       Impact factor: 4.436

6.  Ifosfamide and doxorubicin in the treatment of advanced leiomyosarcomas of the uterus: a Gynecologic Oncology Group study.

Authors:  G Sutton; J A Blessing; J H Malfetano
Journal:  Gynecol Oncol       Date:  1996-08       Impact factor: 5.482

7.  A randomized clinical trial of adjuvant adriamycin in uterine sarcomas: a Gynecologic Oncology Group Study.

Authors:  G A Omura; J A Blessing; F Major; S Lifshitz; C E Ehrlich; C Mangan; J Beecham; R Park; S Silverberg
Journal:  J Clin Oncol       Date:  1985-09       Impact factor: 44.544

Review 8.  Clinical management of uterine sarcomas.

Authors:  Frédéric Amant; An Coosemans; Maria Debiec-Rychter; Dirk Timmerman; Ignace Vergote
Journal:  Lancet Oncol       Date:  2009-12       Impact factor: 41.316

9.  A randomized study of adriamycin with and without dimethyl triazenoimidazole carboxamide in advanced uterine sarcomas.

Authors:  G A Omura; F J Major; J A Blessing; T V Sedlacek; J T Thigpen; W T Creasman; R J Zaino
Journal:  Cancer       Date:  1983-08-15       Impact factor: 6.860

10.  O-methylated catechins from tea leaves inhibit multiple protein kinases in mast cells.

Authors:  Mari Maeda-Yamamoto; Naoki Inagaki; Jiro Kitaura; Takao Chikumoto; Hiroharu Kawahara; Yuko Kawakami; Mitsuaki Sano; Toshio Miyase; Hirofumi Tachibana; Hiroichi Nagai; Toshiaki Kawakami
Journal:  J Immunol       Date:  2004-04-01       Impact factor: 5.422

View more
  6 in total

Review 1.  Hitting the golden TORget: curcumin's effects on mTOR signaling.

Authors:  Christopher S Beevers; Hongyu Zhou; Shile Huang
Journal:  Anticancer Agents Med Chem       Date:  2013-09       Impact factor: 2.505

Review 2.  Designing a broad-spectrum integrative approach for cancer prevention and treatment.

Authors:  Keith I Block; Charlotte Gyllenhaal; Leroy Lowe; Amedeo Amedei; A R M Ruhul Amin; Amr Amin; Katia Aquilano; Jack Arbiser; Alexandra Arreola; Alla Arzumanyan; S Salman Ashraf; Asfar S Azmi; Fabian Benencia; Dipita Bhakta; Alan Bilsland; Anupam Bishayee; Stacy W Blain; Penny B Block; Chandra S Boosani; Thomas E Carey; Amancio Carnero; Marianeve Carotenuto; Stephanie C Casey; Mrinmay Chakrabarti; Rupesh Chaturvedi; Georgia Zhuo Chen; Helen Chen; Sophie Chen; Yi Charlie Chen; Beom K Choi; Maria Rosa Ciriolo; Helen M Coley; Andrew R Collins; Marisa Connell; Sarah Crawford; Colleen S Curran; Charlotta Dabrosin; Giovanna Damia; Santanu Dasgupta; Ralph J DeBerardinis; William K Decker; Punita Dhawan; Anna Mae E Diehl; Jin-Tang Dong; Q Ping Dou; Janice E Drew; Eyad Elkord; Bassel El-Rayes; Mark A Feitelson; Dean W Felsher; Lynnette R Ferguson; Carmela Fimognari; Gary L Firestone; Christian Frezza; Hiromasa Fujii; Mark M Fuster; Daniele Generali; Alexandros G Georgakilas; Frank Gieseler; Michael Gilbertson; Michelle F Green; Brendan Grue; Gunjan Guha; Dorota Halicka; William G Helferich; Petr Heneberg; Patricia Hentosh; Matthew D Hirschey; Lorne J Hofseth; Randall F Holcombe; Kanya Honoki; Hsue-Yin Hsu; Gloria S Huang; Lasse D Jensen; Wen G Jiang; Lee W Jones; Phillip A Karpowicz; W Nicol Keith; Sid P Kerkar; Gazala N Khan; Mahin Khatami; Young H Ko; Omer Kucuk; Rob J Kulathinal; Nagi B Kumar; Byoung S Kwon; Anne Le; Michael A Lea; Ho-Young Lee; Terry Lichtor; Liang-Tzung Lin; Jason W Locasale; Bal L Lokeshwar; Valter D Longo; Costas A Lyssiotis; Karen L MacKenzie; Meenakshi Malhotra; Maria Marino; Maria L Martinez-Chantar; Ander Matheu; Christopher Maxwell; Eoin McDonnell; Alan K Meeker; Mahya Mehrmohamadi; Kapil Mehta; Gregory A Michelotti; Ramzi M Mohammad; Sulma I Mohammed; D James Morre; Vinayak Muralidhar; Irfana Muqbil; Michael P Murphy; Ganji Purnachandra Nagaraju; Rita Nahta; Elena Niccolai; Somaira Nowsheen; Carolina Panis; Francesco Pantano; Virginia R Parslow; Graham Pawelec; Peter L Pedersen; Brad Poore; Deepak Poudyal; Satya Prakash; Mark Prince; Lizzia Raffaghello; Jeffrey C Rathmell; W Kimryn Rathmell; Swapan K Ray; Jörg Reichrath; Sarallah Rezazadeh; Domenico Ribatti; Luigi Ricciardiello; R Brooks Robey; Francis Rodier; H P Vasantha Rupasinghe; Gian Luigi Russo; Elizabeth P Ryan; Abbas K Samadi; Isidro Sanchez-Garcia; Andrew J Sanders; Daniele Santini; Malancha Sarkar; Tetsuro Sasada; Neeraj K Saxena; Rodney E Shackelford; H M C Shantha Kumara; Dipali Sharma; Dong M Shin; David Sidransky; Markus David Siegelin; Emanuela Signori; Neetu Singh; Sharanya Sivanand; Daniel Sliva; Carl Smythe; Carmela Spagnuolo; Diana M Stafforini; John Stagg; Pochi R Subbarayan; Tabetha Sundin; Wamidh H Talib; Sarah K Thompson; Phuoc T Tran; Hendrik Ungefroren; Matthew G Vander Heiden; Vasundara Venkateswaran; Dass S Vinay; Panagiotis J Vlachostergios; Zongwei Wang; Kathryn E Wellen; Richard L Whelan; Eddy S Yang; Huanjie Yang; Xujuan Yang; Paul Yaswen; Clement Yedjou; Xin Yin; Jiyue Zhu; Massimo Zollo
Journal:  Semin Cancer Biol       Date:  2015-12       Impact factor: 15.707

3.  Curcumin targets the AKT-mTOR pathway for uterine leiomyosarcoma tumor growth suppression.

Authors:  Tze Fang Wong; Takashi Takeda; Bin Li; Kenji Tsuiji; Akiko Kondo; Mari Tadakawa; Satoru Nagase; Nobuo Yaegashi
Journal:  Int J Clin Oncol       Date:  2013-05-11       Impact factor: 3.402

Review 4.  Naturally occurring anti-cancer compounds: shining from Chinese herbal medicine.

Authors:  Hua Luo; Chi Teng Vong; Hanbin Chen; Yan Gao; Peng Lyu; Ling Qiu; Mingming Zhao; Qiao Liu; Zehua Cheng; Jian Zou; Peifen Yao; Caifang Gao; Jinchao Wei; Carolina Oi Lam Ung; Shengpeng Wang; Zhangfeng Zhong; Yitao Wang
Journal:  Chin Med       Date:  2019-11-06       Impact factor: 5.455

Review 5.  Hybrid curcumin compounds: a new strategy for cancer treatment.

Authors:  Marie-Hélène Teiten; Mario Dicato; Marc Diederich
Journal:  Molecules       Date:  2014-12-12       Impact factor: 4.411

6.  Possible Therapeutic Use of Natural Compounds Against COVID-19.

Authors:  Nabab Khan; Xuesong Chen; Jonathan D Geiger
Journal:  J Cell Signal       Date:  2021
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.